The first study of the effects of bexarotene in a mouse model of AD reported a reduction in the number of Aβ plaques, in the levels of soluble Aβ, and facilitation of Aβ clearance, through the ApoE related mechanism. This evidence concerns the gene APOE and Alzheimer disease.